Logo image of BCAB

BIOATLA INC (BCAB) Stock Fundamental Analysis

NASDAQ:BCAB - Nasdaq - US09077B1044 - Common Stock - Currency: USD

0.3835  0 (-0.8%)

After market: 0.385 +0 (+0.39%)

Fundamental Rating

3

BCAB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While BCAB seems to be doing ok healthwise, there are quite some concerns on its profitability. BCAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BCAB has reported negative net income.
BCAB had a negative operating cash flow in the past year.
BCAB had negative earnings in each of the past 5 years.
BCAB had a negative operating cash flow in each of the past 5 years.
BCAB Yearly Net Income VS EBIT VS OCF VS FCFBCAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -133.10%, BCAB is not doing good in the industry: 82.94% of the companies in the same industry are doing better.
BCAB has a worse Return On Equity (-489.14%) than 77.56% of its industry peers.
Industry RankSector Rank
ROA -133.1%
ROE -489.14%
ROIC N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
BCAB Yearly ROA, ROE, ROICBCAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAB Yearly Profit, Operating, Gross MarginsBCAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

BCAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCAB has been increased compared to 1 year ago.
The number of shares outstanding for BCAB has been increased compared to 5 years ago.
BCAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCAB Yearly Shares OutstandingBCAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BCAB Yearly Total Debt VS Total AssetsBCAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -16.23, we must say that BCAB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.23, BCAB is doing worse than 81.51% of the companies in the same industry.
There is no outstanding debt for BCAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.23
ROIC/WACCN/A
WACC9.79%
BCAB Yearly LT Debt VS Equity VS FCFBCAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

BCAB has a Current Ratio of 3.52. This indicates that BCAB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.52, BCAB perfoms like the industry average, outperforming 40.75% of the companies in the same industry.
BCAB has a Quick Ratio of 3.52. This indicates that BCAB is financially healthy and has no problem in meeting its short term obligations.
BCAB has a Quick ratio (3.52) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 3.52
BCAB Yearly Current Assets VS Current LiabilitesBCAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.00% over the past year.
Measured over the past years, BCAB shows a quite strong growth in Revenue. The Revenue has been growing by 16.17% on average per year.
EPS 1Y (TTM)51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BCAB will show a small growth in Earnings Per Share. The EPS will grow by 6.27% on average per year.
The Revenue is expected to grow by 31.86% on average over the next years. This is a very strong growth
EPS Next Y8.8%
EPS Next 2Y6.49%
EPS Next 3Y7.08%
EPS Next 5Y6.27%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y31.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BCAB Yearly Revenue VS EstimatesBCAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
BCAB Yearly EPS VS EstimatesBCAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BCAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAB Price Earnings VS Forward Price EarningsBCAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAB Per share dataBCAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.49%
EPS Next 3Y7.08%

More info and screens

0

5. Dividend

5.1 Amount

BCAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOATLA INC

NASDAQ:BCAB (7/11/2025, 8:00:02 PM)

After market: 0.385 +0 (+0.39%)

0.3835

0 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-06 2025-08-06
Inst Owners32.95%
Inst Owner Change0%
Ins Owners8.54%
Ins Owner Change22.63%
Market Cap22.40M
Analysts84
Price Target5.61 (1362.84%)
Short Float %7.92%
Short Ratio7.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.34%
Min EPS beat(2)22.6%
Max EPS beat(2)40.09%
EPS beat(4)4
Avg EPS beat(4)19.34%
Min EPS beat(4)1.51%
Max EPS beat(4)40.09%
EPS beat(8)7
Avg EPS beat(8)14.61%
EPS beat(12)10
Avg EPS beat(12)11.55%
EPS beat(16)11
Avg EPS beat(16)5.14%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34%
PT rev (3m)-34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)-14.96%
EPS NY rev (3m)1.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.04
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.57
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.19
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -133.1%
ROE -489.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 3.52
Altman-Z -16.23
F-Score3
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)10.18%
Cap/Depr(5y)31.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
EPS Next Y8.8%
EPS Next 2Y6.49%
EPS Next 3Y7.08%
EPS Next 5Y6.27%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y31.86%
EBIT growth 1Y42.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.84%
OCF growth 3YN/A
OCF growth 5YN/A